Polatuzumab Vedotin

Category: Cancer



Polatuzumab Vedotin Overview

Polatuzumab vedotin (INN;[4] brand name Polivy, is an antibody-drug conjugate or ADC designed for the treatment of cancer.[5] The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab.[6][7] The drug was developed by Genentech and Roche.[not verified in body] History In June 2019, polatuz...

Read more Polatuzumab Vedotin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Polatuzumab_vedotin

Recent Polatuzumab Vedotin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Polatuzumab Vedotin
  • Injection: 140mg
  • Powder: 140mg/vial, 30mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Polatuzumab Vedotin or a similar ingredient: (1 result)

  • POLIVY Polatuzumab Vedotin-piiq